Vascular diseases

Medtronic Venous Stent Receives U.S. FDA Approval to Treat Venous Outflow Obstruction

Retrieved on: 
Monday, October 26, 2020
Angiology, Medical specialties, Cardiovascular system, Hematology, Veins, Vascular diseases, Thrombosis, Venous translucence, Chronic venous insufficiency

This device is indicated for use in the iliofemoral veins in patients with symptomatic iliofemoral venous outflow obstruction, also known as deep venous obstruction.

Key Points: 
  • This device is indicated for use in the iliofemoral veins in patients with symptomatic iliofemoral venous outflow obstruction, also known as deep venous obstruction.
  • Deep venous obstruction occurs when the veins in the deep venous system become obstructed, blocked and/or compressed causing restricted blood flow to the heart.
  • The FDA approval is based on 12-month results from the ABRE clinical study, presented at the 2020 Charing Cross Symposium.
  • "With FDA approval, we now have this important tool in our arsenal to treat patients with even the most challenging of deep venous lesions."

Global Flow Diversion Aneurysm Treatment Market- Featuring Acandis GmbH, Boston Scientific Corp., Cardinal Health Inc., Among Others

Retrieved on: 
Friday, October 16, 2020
Science, Other Science, Pharmaceutical, Surgery, General Health, Health, Medical devices, Hospitals, Vascular diseases, Aneurysm, Gross pathology, Market analysis, Vascular surgery

The global flow diversion aneurysm treatment market is poised to grow by USD 1.64 billion during 2020-2024 progressing at a CAGR of over 8 % during the forecast period.

Key Points: 
  • The global flow diversion aneurysm treatment market is poised to grow by USD 1.64 billion during 2020-2024 progressing at a CAGR of over 8 % during the forecast period.
  • View the full release here: https://www.businesswire.com/news/home/20201015005745/en/
    Technavio has announced its latest market research report titled Global Flow Diversion Aneurysm Treatment Market 2020-2024 (Graphic: Business Wire)
    The report on the global flow diversion aneurysm treatment market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
  • Download Free Sample Report on COVID-19 Recovery Analysis
    The flow diversion aneurysm treatment market analysis includes the product segment and geographical landscapes.
  • This study identifies the increasing R&D focus as one of the prime reasons driving the flow diversion aneurysm treatment market growth during the next few years.

Endologix Launches ALTO™ Abdominal Stent Graft System in Europe

Retrieved on: 
Thursday, October 15, 2020
Health, Medical devices, Consumer, Surgery, Seniors, Radiology, Cardiology, Medical specialties, Medicine, Clinical medicine, Vascular surgery, Vascular diseases, Aortic aneurysm, IgG4-related disease, Abdominal aortic aneurysm, Aneurysm, Minimally invasive procedure, Endovascular aneurysm repair, Michael L. Marin, Abdominal Aortic Aneurysm (AAA), Endologix

Furthering its mission to transform the treatment of aortic disorders, Endologix LLC today announced the first implant of its ALTO Abdominal Stent Graft, commencing the European commercial release of the recently CE Mark approved endograft.

Key Points: 
  • Furthering its mission to transform the treatment of aortic disorders, Endologix LLC today announced the first implant of its ALTO Abdominal Stent Graft, commencing the European commercial release of the recently CE Mark approved endograft.
  • We are pleased to expand the product launch to include Europe, making ALTO available to our physician partners and patients there as well as in the U.S., commented Prof. Matt Thompson, chief medical officer of Endologix.
  • The ALTO device was specifically chosen for this patient because he felt the patients short, thrombus-lined conical aortic neck could only be treated using ALTO.
  • The company's products are intended for the minimally invasive endovascular treatment of abdominal aortic aneurysms (AAA).

Stroke Management Market Revenue to Cross USD 47B by 2026: Global Market Insights, Inc.

Retrieved on: 
Monday, September 28, 2020
Cardiovascular system, Angiology, Clinical medicine, RTT, Stroke, Thrombectomy, Vascular diseases, Cerebrovascular diseases

However, recent trials have stated thatthrombectomycan be helpful for patients even up to 24 hours after the stroke, thereby driving the market growth.

Key Points: 
  • However, recent trials have stated thatthrombectomycan be helpful for patients even up to 24 hours after the stroke, thereby driving the market growth.
  • Furthermore, the rising adoption of mobile stroke treatment units for treatment in stroke patients will enhance the industry's progression.
  • The stroke management market for the transientischemicattack (TIA) segment is expected to experience significant growth during the forecast period.
  • The carotid ultrasound segment in the stroke management market accounted for around USD 4 billion in 2019.

JanOne Issues September 2020 Shareholder Letter Updating Investors on Recent Pharma Asset Potential for Peripheral Artery Disease

Retrieved on: 
Tuesday, September 22, 2020
RTT, Vascular diseases, Peripheral artery disease, Artery disease, Medical specialties, Organ systems, Kawasaki disease

The letter highlights JanOne's recent updates on the Company's corporate and clinical developments.

Key Points: 
  • The letter highlights JanOne's recent updates on the Company's corporate and clinical developments.
  • The initial path forward is to continue the development of our proprietary, high-value, late-stage asset, JAN101 for the treatment of peripheral artery disease (PAD)," said Tony Isaac, Chief Executive Officer of JanOne.
  • "Additionally, we continue to pursue additional indications for JAN101, like the recently announced potential application for the treatment of vascular complications associated with COVID-19.
  • Its lead candidate JAN101 is for treating peripheral artery disease (PAD), a condition that affects over 8.5 million Americans.

Compelling Outcomes with TCAR vs. CEA in Patients with Carotid Artery Stenosis Published in the Annals of Surgery

Angiology, TCAR, Medical specialties, Anatomy, Vascular diseases, Carotid artery stenosis, Common carotid artery, Stroke, Artery disease, Carotid artery, Neurosurgery, Vascular surgery

These promising outcomes will likely increase the role of TCAR in the management of carotid artery stenosis.

Key Points: 
  • These promising outcomes will likely increase the role of TCAR in the management of carotid artery stenosis.
  • The study evaluated patients who underwent carotid procedures between 2016 and 2019, with 6,384 patients in each group analyzed using propensity score matching.
  • Additionally, there were no statistical differences noted between TCAR and CEA for in-hospital stroke/death (TCAR, 1.6%; CEA, 1.6%, p=0.945) as well as stroke (TCAR, 1.4%; CEA, 1.4%, p=0.881) and death (TCAR, 0.4%; CEA, 0.3%, p=0.662).
  • The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR).

Prevencio Develops Highly Accurate, Artificial Intelligence-driven Blood Test for Kawasaki Disease

Retrieved on: 
Thursday, September 17, 2020
Research, Technology, Medical devices, Infectious diseases, Children, Cardiology, Software, Consumer, Health, Science, Medical specialties, RTT, Vascular diseases, Organ systems, Clinical medicine, Pediatrics, Kawasaki disease, Vascular disease, Kawasaki, Cardiovascular disease, Prevencio HART Tests, Prevencio, Inc.

Prevencio, Inc. today announces the development of a highly accurate blood test, HART KD, for diagnosis of Kawasaki disease.

Key Points: 
  • Prevencio, Inc. today announces the development of a highly accurate blood test, HART KD, for diagnosis of Kawasaki disease.
  • Kawasaki disease is a rare but fatal childhood disease that causes inflammation in the walls of arteries throughout the body.
  • Prevencio used their long-standing, certified laboratory partner, Myriad RBM, to conduct protein measurements on blood samples collected from children with Kawasaki disease and is developing commercial options for offering HART KD for children suspected of Kawasaki disease.
  • Powered by Artificial Intelligence (AI), Prevencio is revolutionizing blood tests for cardiovascular disease and custom diagnostics.

Perivascular Fat Inflammation: From Atherosclerosis to COVID-19, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, September 16, 2020
Medical specialties, Clinical medicine, Medicine, RTT, Vascular diseases, Animal physiology, Human physiology, Immunology, Inflammation, Atherosclerosis, Paul Ridker

The role of inflammation in atherosclerosis has recently gained further prominence with clinical trials such as CANTOS and COLCOT, showing that reducing systemic inflammation improves clinical outcome.

Key Points: 
  • The role of inflammation in atherosclerosis has recently gained further prominence with clinical trials such as CANTOS and COLCOT, showing that reducing systemic inflammation improves clinical outcome.
  • There is now an increased focus on targeting residual coronary inflammatory risk as a viable therapeutic target in cardiovascular drug development.
  • For more information or to register for this event, visit Perivascular Fat Inflammation: From Atherosclerosis to COVID-19 .
  • Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

Flow Diversion Aneurysm Treatment Market- Roadmap for Recovery from COVID-19 | Improvements In Detection of UIAs to boost the Market Growth | Technavio

Retrieved on: 
Wednesday, September 16, 2020
Infectious diseases, General Health, Health, Other Health, Vascular diseases, Aneurysm, Gross pathology, Coronavirus disease, Medical specialties, Branches of biology, Clinical medicine

The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Key Points: 
  • The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
  • View the full release here: https://www.businesswire.com/news/home/20200916005066/en/
    Technavio has announced its latest market research report titled Global Flow Diversion Aneurysm Treatment Market 2020-2024.
  • (Graphic: Business Wire)
    Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied.
  • Flow Diversion Aneurysm Treatment Market 2020-2024: Segmentation
    Flow Diversion Aneurysm Treatment Market is segmented as below:

Center for Vein Restoration Committed to Peer-to-Peer Education and Increasing Awareness of CVI

Retrieved on: 
Tuesday, September 8, 2020
Circulatory system, Cardiovascular system, Vascular diseases, Chronic venous insufficiency, Lymphedema, Venous insufficiency, Insufficiency, Vein, CVI

GREENBELT, Md., Sept. 8, 2020 /PRNewswire-PRWeb/ -- Center for Vein Restoration (CVR) concluded their National Summer Series of free 1.0 category one Continuing Medical Education (CME) credit webinars on August 20, 2020.

Key Points: 
  • GREENBELT, Md., Sept. 8, 2020 /PRNewswire-PRWeb/ -- Center for Vein Restoration (CVR) concluded their National Summer Series of free 1.0 category one Continuing Medical Education (CME) credit webinars on August 20, 2020.
  • Topics ranged from lymphedema to leg pain, but all centered on diagnosing and treating one underlying cause: Chronic Venous Insufficiency (CVI).
  • Accredited CME offerings presented by CVR physicians have long been a cornerstone of CVR's commitment to education.
  • Center for Vein Restoration (CVR) is the largest physician-led practice treating vein disease in the country.